Merrill Lynch analyst Michael Cherny maintained a Buy rating on CVS Health Corp (NYSE:CVS) on Tuesday, setting a price target of $83, and that is approximately 9.11 % above the existing share price of $76.07.
Cherny expects CVS Health Corp to submit earnings per share (EPS) of $0.93 for the first quarter of 2021.
The analysts priced targets range from a high of hundred one dolars to a low of $61.
In its latest earnings report, released on 09/30/2020, the company found a quarterly revenue of $67.06 billion and a net benefit of $3.25 billion. The company’s market cap is $99.57 billion.
Based on TipRanks.com, Merrill Lynch analyst Michael Cherny is presently ranked with 4 stars on a 0-5 stars ranking scale, with an average return of 11.5 % along with a 60.53 % success rate.
CVS Health Corp. engages in the provision of health care services. It operates through the following segments: Pharmacy Services, Long or retail Term Care, Health Care Benefits, and Corporate. The Pharmacy Services segment offers pharmacy benefit management strategies. The retail or Long Term Care segment has offering of prescription drugs and assortment of general merchandise.
The Health Care Benefits segment offers traditional, voluntary and consumer-directed health insurance products and related services, which includes medical, pharmacy, dental, behavioural health, healthcare management abilities. The Corporate segment involves in offering administrative services as well as management. The company was developed by Stanley P. Goldstein as well as Ralph Hoagland in 1963 and it is headquartered in Woonsocket, RI.